Figure 1. (A) Baseline contrast-enhanced CT scan of melanoma patient presenting with metastases in the liver and lymph ... Figure 1. (A) Baseline contrast-enhanced.

Slides:

Advertisements

Similar presentations

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.

Advertisements

Figure 5: Three-dimensional reconstruction of the CT scan showing the trapped air in the head and neck region. From: Distinct subcutaneous emphysema following.

From: Learning by Working in Big Cities

Fig. 1 Nodes in a conceptual knowledge graph

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

From: Detection of Bacteriuria by Canine Olfaction

Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:

Abstract From: Lung transplantation after ex vivo lung perfusion in two Scandinavian centres Eur J Cardiothorac Surg. Published online October 29, 2018.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

ADAb: anti-drug antibody.

Figure 1. Overview of the workflow of NetworkAnalyst 3.0.

FIGURE 1 Kidney biopsies of Patients 1 and 2

Figure 1 Hazard ratios as a function of annual mean PM2

Figure 1 Schematic representation of the extreme SVD design in the 3C-Dijon study. Unless provided in the caption above, the following copyright applies.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Flow chart of patient enrollment and exclusion

Figure 1. Ratios of observed to expected numbers of exon boundaries aligning to boundaries of domain and disorder ... Figure 1. Ratios of observed to expected.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Fig. 1 Kaplan-Meier plot of cumulative incidence of cancer onset following dermatomyositis diagnosis stratified ... Anti-TIF1-Ab: anti-transcriptional.

Figure 1 Flortaucipir PET MUBADA/PERSI SUVr at baseline, 9 and 18 months for individual subjects. Each subject is ... Figure 1 Flortaucipir PET MUBADA/PERSI.

Fig. 1 Mean change from baseline in ANC ± s. e

Point estimates with ... Point estimates with 95% CI. HR: hip replacement; KR: knee replacement. Unless provided in the caption above, the following copyright.

Figure 1. (A) Ab+ patients showed significantly more often a cognitive impairment compared with ab− patients [57.1% ... Figure 1. (A) Ab+ patients showed.

FIGURE 1 Participant flow diagram. Exercise Counseling Clinic (ECC).

Graph 1. The number of homicide cases per year discussing neuro-evidence. Unless provided in the caption above, the following copyright applies to the.

Figure 1. Analysis of human TRIM5α protein with Blast-Search and PhyML+SMS ‘One click’ workflow. (A) NGPhylogeny.fr ... Figure 1. Analysis of human TRIM5α.

Figure 2. Natural history of chlamydia transmission, with arrows showing the transitions between health states. Figure 2. Natural history of chlamydia.

Figure 1 Nelson-Aalen estimates of the cumulative incidence rates for patients on versus off IST. ON = optic neuritis; ... Figure 1 Nelson-Aalen estimates.

Figure 1. A, Crude incidence rates per 100 person-years of follow-up and 95% confidence intervals for each solid organ ... Figure 1. A, Crude incidence.

FIGURE 1 Study consort diagram

Fig. 2 Case 2. Levels of serum creatinine and anti-GBM antibodies before and during treatment with cyclophosphamide, ... Fig. 2 Case 2. Levels of serum.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Illustration of DGR systems and their prediction using myDGR

FIGURE 1 Food groups consumed (mean, g/d) among US infants and young children by age group and tertile of mean ... FIGURE 1 Food groups consumed (mean,

Figure 1 Study flowchart and patient flow

Figure 1. Prediction result for birch pollen allergen Bet v 1 (PDB: 1bv1), as obtained by comparison to the cherry ... Figure 1. Prediction result for.

Figure 1. PaintOmics 3 workflow diagram

Figure 1. Schematic diagram of solar energy and coal-fired power generation system. Unless provided in the caption above, the following copyright applies.

Figure 1. Uncertainty reduction, value creation, and appropriation in two case studies. Unless provided in the caption above, the following copyright applies.

Figure 1 Ratio of the geometric mean concentration of hsTnT (A) and sST2 (B) at baseline (BL) and each subsequent ... Figure 1 Ratio of the geometric mean.

Figure 1. Time to clinical stability (a) and time to defervescence (b) in patients with pneumococcal pneumonia. ... Figure 1. Time to clinical stability.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1. MERMAID web server interface (Start page, Parameter page): MERMAID provides two ways to submit a protein ... Figure 1. MERMAID web server interface.

Figure 1. Yvis platform overview

Figure 1. The framework of NetGO with seven steps

Figure 1 Patient disposition

Figure 1 Diagram of patient and procedural follow-up for Cohorts A, B, and C. Cohort A: 6-month OCT and 12-month OCT, ... Figure 1 Diagram of patient and.

Figure 1. Overview of BEECH study exploratory analysis

Figure 1. Workflow of the analysis to estimate the number of true human miRNAs. Samples containing NGS data were ... Figure 1. Workflow of the analysis.

Figure 1 BM community in the normozoospermic and iNOA human testis parenchyma. Quantification of the 16 S copies/ng in ... Figure 1 BM community in the.

Fig. 1. —Synteny analysis of melon chromosome 1 (brown) and cucumber chromosome 7 (green) based on melon-cucumber ... Fig. 1. —Synteny analysis of melon.

Figure 1. Trial profile. (A) Part A and (B) part B

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Figure 1 Distribution of WCD use days in WEARIT-II

Figure 1 Correlation between en face Oil-Red O staining and aortic root lesion size vs. plasma cholesterol and ... Figure 1 Correlation between en face.

Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by ... Figure 1. The proportion of CSBM.

Figure 1 Genetic results. No case had more than one diagnostic result

Figure 1. Prevalence of parasitic infection and anemia among the children. Unless provided in the caption above, the following copyright applies to the.

Source:Zimnisky (2014). Source:Zimnisky (2014).

Figure 1 Mechanisms of mitral regurgitation.

Fig. 2. Genetic differentiation among populations and individuals

Figure 1 ABCDE of primary prevention.2

Figure 1. Hepatitis C screening and diagnostic algorithm at the MSF clinic, Karachi, Pakistan, March 2016–September ... Figure 1. Hepatitis C screening.

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Presentation transcript:

Figure 1. (A) Baseline contrast-enhanced CT scan of melanoma patient presenting with metastases in the liver and lymph ... Figure 1. (A) Baseline contrast-enhanced CT scan of melanoma patient presenting with metastases in the liver and lymph nodes in the axilla and subclavicular area. (B) Follow-up scan of the same patient showing complete response in the axillary region and partial response of the lesions in the liver and neck. (C) Baseline CT scan of an NSCLC patient presenting lesion in the left lung, that showed progression at a later FU CT (data not shown). (D) Baseline CT scan of a melanoma patient presenting lesions in the right lung that showed response at a later FU CT (data not shown). (E) Schematic representation of the radiomics feature extraction process. (F) Schematic of the machine learning process. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Ann Oncol, Volume 30, Issue 6, 21 March 2019, Pages 998–1004, https://doi.org/10.1093/annonc/mdz108 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 2. (A) Response kinetics curve depicting individual lesion responses (as dots) on a patient-to-patient basis. ... Figure 2. (A) Response kinetics curve depicting individual lesion responses (as dots) on a patient-to-patient basis. (B) One-year survival plot for all analyzed patients (C) for melanoma patients only, (D) for NSCLC patients only. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Ann Oncol, Volume 30, Issue 6, 21 March 2019, Pages 998–1004, https://doi.org/10.1093/annonc/mdz108 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 3. Performance of the selected classifier on the independent test set for NSCLC lesions (A) and melanoma lesions ... Figure 3. Performance of the selected classifier on the independent test set for NSCLC lesions (A) and melanoma lesions (B). (C) Patient level response at first follow-up and (D) prognostic performance of the imaging biomarker on a patient level. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com Ann Oncol, Volume 30, Issue 6, 21 March 2019, Pages 998–1004, https://doi.org/10.1093/annonc/mdz108 The content of this slide may be subject to copyright: please see the slide notes for details.